HOLLYWOOD, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, conformity assessment, and consulting solutions, announced today that it has been awarded a three-year, $19.5 million construction inspection contract by the California Department of Transportation (Caltrans) District 7 in... Read more
New ecommerce expansion with AI 3D-Photography Tools TORONTO, ON / ACCESSWIRE / April 18, 2024 / Nextech3D.AI (OTCQX:NEXCF) (CSE:NTAR) (FSE:EP2), a patented 2D-3D Generative AI-Powered 3D model supplier (Patent #11,948,248) for Amazon, Miele, P&G, Kohls, Wesfarmers Group ``Bunnings" (Australia's largest listed company) and other major e-commerce retailers is adding Digital Photography and dynamic product... Read more
CASTLE ROCK, Colo., April 18, 2024 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), an industry leader in vertically integrated Bitcoin (“BTC”) mining, announced today that it has successfully energized the substation at the Company’s Corsicana Facility. “Two years ago, we purchased 265 acres of land in Navarro County, Texas, driven by our vision to build the world's largest... Read more
Innovative Bitcoin Financial Product: DeFi Technologies, through its subsidiary Valour, has launched the first Short Spot Bitcoin ETP in the Nordics, known as Valour Short Bitcoin (SBTC) SEK (ISIN: CH1149139649), providing a novel way for investors to profit from or hedge against Bitcoin's price movements. Strategic Market Placement: The Short Spot Bitcoin ETP is now trading on the Nordic Growth Market,... Read more
Total Revenue Doubled with 100% Y/Y Growth from March of last year March Self-Mining Business Revenue up 182% Y/Y March Co-Location Business Revenue up 54% Y/Y March Total Revenue of about $5.44 million MIDLAND, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure company, announced today its unaudited business and... Read more
NEW YORK, April 18, 2024 /CNW/ - Galaxy Digital Holdings Ltd. (TSX: GLXY) ("Galaxy") announced that its affiliate, Galaxy Asset Management, ("GAM"), reported preliminary assets under management of $7.8 billion as of March 31, 2024. The 23.3% decrease in preliminary AUM compared to the prior month was primarily driven by the liquidation of assets associated with an ongoing opportunistic mandate, partially... Read more
Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical... Read more
SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023. The Company placed 313 da Vinci... Read more
Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties TORONTO / Apr 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company... Read more
Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative... Read more
IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its... Read more
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s... Read more
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing... Read more
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of a Complete Response Letter (“CRL”) for its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee... Read more
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces receipt of clearance from the U.S. Food and Drug Administration... Read more
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry... Read more
CHANGZHOU, China, April 17, 2024 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we," "our," or the "Company"), a leading short-distance transportation solutions provider in China, today announced that it entered into a five-year strategic cooperation framework agreement (the "Agreement") with Woteam New Energy (Guangdong) Co., Ltd. ("Woteam"), a high-tech enterprise engaged in the research,... Read more
SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules. The rapid growth in the... Read more
IRVINE, Calif., April 17, 2024 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO), a company coached by ATIF Holdings Limited (NASDAQ: ATIF, hereinafter referred to as "ATIF"), announces its fiscal year 2023 financial results following a $5.85 million initial public offering. Fiscal year Revenue increased by 32.9% during the reporting period(reached US $115 million) and gross margin increased 550 basis points to 31.2%.... Read more
Innovative Bitcoin ETPs Launch: DeFi Technologies Inc. and Valour partner with the Core Foundation to launch groundbreaking Exchange Traded Products (“ETPs”), including a first-of-its-kind Yield Bearing BTC ETP and a novel Core ETP, leveraging Core Chain's unique blockchain features. Yield Opportunities Through BTC: The Yield Bearing BTC ETP introduces a new era for Bitcoin as an actively yielding investment,... Read more
Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI... Read more
TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced the expansion of its pipeline into metabolic and related disorders including weight loss and liver health. The Company has... Read more
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants. Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a... Read more
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of... Read more
VANCOUVER, BC, April 17, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3... Read more
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, is pleased to announce that,... Read more
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV:... Read more
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our... Read more
NextNav Files FCC Petition for Rulemaking, Following Court’s Approval of Previously Announced Acquisition of Spectrum Licenses Innovative Spectrum Solution Supports NextGen PNT Technology with 5G Broadband MCLEAN, Va., April 16, 2024 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN) (“NextNav” or the “Company”) a leader in next generation positioning, navigation, timing (“PNT”) and 3D geolocation, today filed a... Read more
The largest machine tool reseller in the US will offer for the first time the unique benefits of additive manufacturing for its large base of customers EDEN PRAIRIE, Minn. & REHOVOT, Israel / Apr 16, 2024 / Business Wire / Stratasys Ltd. (NASDAQ: SSYS) announced today that it has entered into an agreement to be the exclusive polymer 3D printing partner of Select Additive Technologies, a division of Morris... Read more
TURIN, Italy / Apr 16, 2024 / Business Wire / Tyvak International SRL (“Tyvak International”), a Torino, Italy-based subsidiary of Terran Orbital Corporation (NYSE: LLAP) and a leading European provider of nano and microsatellites, announced the successful launch of Fleet Space Technologies’ Centauri-6 satellite, which was developed in collaboration with Tyvak International. The satellite was launched aboard the... Read more
MENLO PARK, Calif., April 16, 2024 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN) today announced the notice of allowance for a new patent, 17/812,072, for the Company's autonomous vehicle (AV) solutions. This patent covers the generation of a compensated environmental model by applying methods to address challenges that arise from using sensors that are in motion while collecting data and... Read more
FY 2023 Revenues up 32.9% to $115.0 Million on Strong Sales of Powersports Vehicles and Pontoon Boats FY 2023 Gross Margin Grew 550 basis points to 31.2% FY 2023 Net Income up 150% to $10.4 Million Closed $5.85 Million Initial Public Offering, Began Trading on Nasdaq Under Ticker Symbol "MAMO" GARLAND, Texas, April 16, 2024 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo"), a manufacturer and... Read more
Q4 Revenue of $3.5 million, up 41% year over year; and Full Year Revenue of $12.7 million, down 12% year over year Q4 operating loss of $5.2 million, a 35% improvement year over year; and Full Year operating loss of $21.1 million, a 52% improvement year over year Company expands its services to a larger commercial population as well as eligible self-insured groups with a health plan customer Company completes... Read more
Completion of partially built structures will increase total operational infrastructure at Denton data center to 197 MW, total Company-owned infrastructure to 817 MW Completion expected by end of second quarter 2024 Expansion highlights strategic advantage of owning and controlling infrastructure and access to power AUSTIN, Texas / Apr 16, 2024 / Business Wire / Core Scientific, Inc. (Nasdaq: CORZ) ("Core... Read more
Greenfield site energized in 78 days, less than three months after breaking ground Cost to mine a Bitcoin at site expected to be 30% lower than cost at hosted facilities due to favorable energy profile MIAMI, April 16, 2024 (GLOBE NEWSWIRE) -- Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America’s... Read more
Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH. Subject recruitment... Read more
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an... Read more
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today... Read more
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug TARRYTOWN, New York, April... Read more
COPYRIGHT ©2022 GREEN STOCK NEWS